Topics

Human medicines European public assessment report (EPAR): Zalmoxis, allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I vi

06:35 EST 14 Feb 2020 | European Medicines Agency

Human medicines European public assessment report (EPAR): Zalmoxis, allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2), Hematopoietic Stem Cell Transplantation,Graft vs Host Disease, Date of authorisation: 18/08/2016, Revision: 1, Status: Withdrawn

Original Article: Human medicines European public assessment report (EPAR): Zalmoxis, allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I vi

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Zalmoxis, allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I vi"

Quick Search

Relevant Topics

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...

Transplantation
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...